BETTA PHARMACEUTICALS: MCLA-129 is currently exploring indications in the field of lung cancer
On August 19th, BETTA PHARMACEUTICALS responded to investor inquiries on the interactive platform, stating that MCLA-129 is a bispecific antibody targeting both EGFR and c-Met. It is currently exploring indications in the field of lung cancer. A recent Phase II study related to driver gene positivity and MET amplification has completed the enrollment of its first patient. The company will promptly disclose any significant research progress
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments